Showing results (291-300 of 686) with videos related to
Sort By:
Pageof 69
Alimentary Pharmacology & Therapeutics|June 17, 2023
Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trialManuel Romero-Gómez, Matthew J Armstrong, Jesús Funuyet-Salas, et al.The New England Journal of Medicine|November 13, 2020
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisPhilip N Newsome, Kristine Buchholtz, Kenneth Cusi, et al.Journal of Hepatology|June 28, 2011
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastographyR Todd Stravitz, Ton Lisman, Velimir A Luketic, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 25, 2013
Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathyKevin D Mullen, Arun J Sanyal, Nathan M Bass, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2019
Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective StudyFrancesco Baratta, Daniele Pastori, Francesco Angelico, et al.Journal of Hepatology|June 28, 2025
Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitisArun J Sanyal, Jorg Taubel, Prajakta Badri, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2020
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic SteatohepatitisMohammad Shadab Siddiqui, Michael O Idowu, Deven Parmar, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 24, 2022
Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled TrialsJasmohan S Bajaj, Tarek I Hassanein, Nikolaos T Pyrsopoulos, et al.JHEP Reports : Innovation in Hepatology|January 3, 2022
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitisYi Luo, Benjamin E Decato, Edgar D Charles, et al.Hepatology (Baltimore, Md.)|March 28, 2008
Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfectionRichard K Sterling, Melissa J Contos, Paula G Smith, et al.Pageof 69